EN
HI
Summary
As of 16 Sep, 2026, Concord Drugs stock price is ₹77.5. During the trading session, the stock has moved between an intraday low of ₹76.80 and an intraday high of ₹79.85. Over the last 52 weeks, Concord Drugs has traded between ₹61.00 and ₹92.52.
The stock has recorded a trading volume of 2,584 shares,. Its Average Traded Price (ATP) is ₹78.00, while the Last Traded Quantity at the Last Traded Price (LTQ@LTP) is 45 @ ₹77.50.
Concord Drugs has an upper circuit limit of ₹95.36 and a lower circuit limit of ₹63.58. The total value traded stands at ₹2.02 L, and the delivery percentage for the day is 51.28%.
The stock is currently traded with a market lot size of 1. Concord Drugs also offers a dividend yield of 0%.
Concord Drugs Share Price Chart
Concord Drugs Share Key Metrics
Volume
2584.00
Market Cap
104.70 CR
LTQ@LTP
45@77.50
ATP
78
Var Margin
25 %
Circuit Range
63.58-95.36
Delivery %
51.28 %
Value
2.02 L
ASM/GSM
No
Market Lot
1
Concord Drugs Fundamentals
P/E Ratio
51.05
P/B Ratio
2.11
Div. Yield
0
Sector P/E
40.7
Sector P/B
3.52
Sec. Div. Yield
0.51
Concord Drugs Resistance and Support
Pivot 79.95
Resistance
First Resistance
81.88
Second Resistance
84.28
Third Resistance
86.21
Support
First Support
77.55
Second Support
75.62
Third Support
73.22
Concord Drugs Historical Data
| Day | Open | Close | Change(%) | Day High | Day Low |
|---|---|---|---|---|---|
| Wed Sep 16 2026 | 78.13 | 77.5 | -2.48% | 79.85 | 76.8 |
| Tue Sep 15 2026 | 78.12 | 79.47 | -0.24% | 82.34 | 78.01 |
| Fri Sep 11 2026 | 80.9 | 79.66 | -1.53% | 82.5 | 78.26 |
Concord Drugs Corporate Actions
| Date | Agenda |
|---|---|
| 2026-08-10 | Quarterly Results |
| 2026-05-27 | Audited Results |
| 2026-02-14 | Quarterly Results |
| 2025-11-13 | Quarterly Results |
| 2025-08-08 | Quarterly Results |
| 2025-07-03 | Preferential issue of shares |
| 2025-06-27 | Preferential Issue of shares & Others |
| 2025-05-23 | Audited Results |
| 2025-03-17 | Preferential Issue of shares & Others |
| 2025-03-13 | Preferential Issue of shares & Others |
| 2025-01-11 | Quarterly Results |
| 2024-11-13 | Quarterly Results |
| 2024-08-09 | Quarterly Results |
Concord Drugs News
Concord Drugs Ltd - 538965 - Intimation Of Record Date For 31St AGM
Concord Drugs has fixed September 23, 2026, as the record date. This is to determine the shareholders eligible for e-voting at its 31st Annual General Meeting, scheduled for September 30, 2026.
Sep 07 2026 19:28:01
Concord Drugs Ltd - 538965 - Board Meeting Outcome for Annual General Meeting To Be Held On 30.09.2026
Concord Drugs' Board of Directors approved the notice for the 31st Annual General Meeting to be held on September 30, 2026. The board also approved the company's FY26 financial statements, book closure dates, and re-appointments of the Chairman & MD, Statutory Auditors, and Independent Directors.
Sep 07 2026 19:12:48
Concord Drugs Management
| Name | Position |
|---|---|
| S Nagi Reddy | Chairman & Managing Director |
| S Koni Reddy | Whole Time Director & Chief Financial Officer |
Concord Drugs Similar Stocks
Raaj Medisafe India Ltd.
102.00
1.77 (1.77%)
Mercury Laboratories Ltd.
781.00
1.00 (0.13%)
Makers Laboratories Ltd.
179.95
8.85 (5.17%)
Bharat Immunologicals & Biologicals Corporation Ltd.
15.00
0.18 (1.21%)
Pharmaids Pharmaceuticals Ltd.
30.00
0.18 (0.60%)
Everest Organics Ltd.
254.00
2.65 (1.05%)
Aspira Pathlab & Diagnostics Ltd.
102.00
2.25 (2.26%)
Godavari Drugs Ltd.
109.80
0.90 (0.83%)
Concord Drugs FAQs
The Buying Price of Concord Drugs share is 77.5 For live prices and instant trading, you can log in to your Choice trading account or open a Free Demat account with Choice.
To buy Concord Drugs stocks, log in to your Choice trading account. If you don’t have one, open a Choice Demat account. Then, add funds, search for Concord Drugs, choose your preferred order type, and place the trade.
The Price-to-earnings (P/E) ratio of Concord Drugs shares is 51.05. You can compare it with the sector average for relative valuation.
The Price to Book (P/B) ratio Concord Drugs shares is 2.11. Useful to assess the stock's value relative to its book value.
To assess Concord Drugs’s valuation compare Sector P/E, P/B which are 40.7 & 3.52 with sector averages, along with growth rates and financial metrics.
The Market Cap of Concord Drugs is 104.70 CR. It indicates the company's size category and trading liquidity.
The 52 week high and low prices of Concord Drugs share price is 92.52 & 61.00. They indicate price extremes, trading ranges, volatility measures, potential support/resistance, and price momentum.
Concord Drugs belongs to the Healthcare sector.
Open Your Free
Demat Account Now!
AMC for First Year- Auto Square Off Charges
13 Lakh+ Clients
Expert-Backed
Premium Tools
Open Your Free
Demat Account Now!
- AMC For First Year
- Account Opening Fee
- 13 Lakh+ Clients
- Expert-Backed
- Premium Tools
Invest in CONCORD
